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Abstract
A high-performance liquid chromatographic method for the determination of ofloxacin in human plasma and urine was
developed. The method involved deproteinisation of the sample with perchloric acid and analysis of the supernatant using a
reversed-phase C column and fluorescence detection at an excitation wavelength of 290 nm and an emission wavelength of18
460 nm. The assay was linear from 0.5 to 10.0 mg/ml. The relative standard deviation of intra- and inter-day assays was
lower than 5%. The average recovery of ofloxacin from plasma was 93%. The method was evaluated in samples from
healthy subjects whose drug levels were already measured by microbiological assay. Ó 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction tuberculosis and OFX appears to be as useful as
ethambutol [3].
Ofloxacin (OFX) is a fluoroquinolone antimicro- Monitoring of OFX concentrations in body fluids
bial agent having a high antibacterial activity against may be valuable to adjust the drug dosage and to
gram positive and gram negative bacteria in vitro and study drug–drug interactions when co-administered
in vivo [1]. The mechanism of the activity is based with other anti-tuberculosis drugs. Several high-per-
on the inhibition of the DNA-gyrase of the bacteria. formance liquid chromatography (HPLC) methods
In vitro studies had shown that OFX has early have been developed for measuring OFX concen-
bactericidal activity against Mycobatcerium tuber- tration in body fluids, based on the natural fluores-
culosis [2]. The efficiency of OFX, rifampicin cence of the quinolone nucleus. In previously pub-
(RMP) and isoniazid (INH) was prospectively com- lished methods, the extraction procedures used were
pared with the regimen of ethambutol (EMB), RMP tedious and the yield was not sufficient [4–7]. A
and INH for the primary treatment of pulmonary simple and rapid assay procedure using the sample
preparation as described in Ref. [8] and the mobile
phase as given in Ref. [9] was developed by us. The
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directly into the reversed-phase HPLC column and tion 8 and gain 10. The chromatogram was run for
detection using fluorescence emission. 10 min at a flow-rate of 1.5 ml /min.
The aim of this study was to develop and validate
a simple and rapid HPLC assay for measuring OFX
levels in plasma and urine that is free of interference 2.3. Preparation of standard solution
from other anti-tuberculosis drugs. After the valida-
tion, the method was evaluated in samples collected A stock standard (1 mg/ml) was prepared by
from healthy volunteers who were administered OFX dissolving OFX in 0.1 M HCl initially, and then
alone or in combination with RMP. The results were made up to the volume with Milli-Q water. The
compared with those of microbiological assay working standards of OFX in concentrations ranging
(MBA) currently in use in our laboratory [10]. from 0.5 to 10.0 mg/ml were prepared in plasma or
urine diluted 1:50 with Milli-Q water. The plasma
standards were prepared using horse plasma from the
2. Experimental King Institute, India.
2.1. Chemicals
2.4. Precision
OFX tablets were obtained from Dee Pharma
(India). Pure OFX standard was from Sigma (St. The precision of the method was evaluated by
Louis, MO, USA). Acetonitrile, HPLC grade was analysing pooled human plasma samples containing
from Merck (India) and the chemicals disodium three different concentrations of OFX. The within-
hydrogenphosphate and orthophosphoric acid used day and between-day variations were determined by
were of analytical grade. Deionised water was pro- assaying each sample in triplicate for 3 days.
cessed through a Milli-Q water purification system
(Millipore, USA).
2.5. Recovery
2.2. Chromatographic system
For the recovery experiment, the same-pooled
The HPLC system consisted of a Crystal 2000 human plasma samples containing previously de-
Series HPLC pump (ATI UNICAM, UK) equipped termined concentrations of OFX were spiked with 1,
with a PU 4027 fluorescence detector (PyeUnicam, 2 and 4 mg/ml OFX and assayed. The percentage of
UK). A Rheodyne manual injector with a 100-ml recovery was calculated by dividing sample differ-
sample loop (Rheodyne, USA) attached was used for ences with the added concentrations.
loading the sample. The data collection and integra-
tion were done using a PU 6020 data capturing unit
and PU 6000 software (PyeUnicam). Quantitation 2.6. Samples
was achieved on the basis of peak height of cali-
bration standards. The analytical column was a YMC Sixty plasma and 24 urine samples were obtained
pack ODS.A, 25034.6 mm I.D., 5 mm particle size from 12 healthy volunteers admitted in a recent study
with matched guard column (YMC, USA). on pharmacokinetics of OFX and stored at 2208C.
The mobile phase consisted of 50 mM phosphate The plasma samples represented serial samples
buffer (pH 2.6 adjusted with 1.5 M disodium hydro- drawn at 1, 2, 3, 6 and 8 h following a single oral
genphosphate)–acetonitrile (82:18, v /v). Before the dose of 15 mg/kg OFX alone (six subjects) or in
preparation of the mobile phase, the phosphate buffer combination with 15 mg/kg of RMP (six subjects).
and acetonitrile were degassed separately using a Urine was collected over the period of 0–4 and 4–8
Millipore vacuum pump. The fluorescence detector h after the administration of the drug. These samples
was set up at an excitation wavelength of 290 nm were previously analysed for OFX concentrations by
and an emission wavelength of 460 nm with attenua- MBA.
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2.7. Sample preparation
To 0.5 ml each of the calibration standards and
test samples, 0.3 ml of 7% perchloric acid was
added, vortex-mixed for 1 min and centrifuged at
2500 rpm for 15 min. A 100-ml volume of the
supernatant was directly injected to the column.
Urine samples were suitably diluted (1:50, 1:100 and
1:200) and then treated the same way as plasma.
3. Results and discussion
Several HPLC methods have been described to
measure OFX levels in plasma and urine for thera-
peutic monitoring. A survey of these papers revealed,
that some of them are quite complex and lengthy
because of the extraction step in sample preparation
[6,7]. The mobile phase containing ion-pair reagents
such as, 1-heptanesulphonic acid and tetrabutylam-
monium hydrogen sulphate were used [5,8], which
could cause problem in column maintenance. In
Fig. 1. Chromatograms of drug-free plasma (a), and of (b) OFX in
contrast, the present method has the advantages of plasma (4.7 mg/ml) and (c) urine (3.8 mg/ml). Peak 25OFX.being simple and rapid. The technique involved
simple steps like deprotenisation /dilution and since
standards ranged from 0.5 to 10.0 mg/ml. A linear
there was no extraction step, the sample preparation
relationship was observed between peak heights and
time was shorter (15 min) and there was no loss of the concentrations over this range with correlation
the analyte. The pH of the mobile phase was 2.6 at
coefficients ranging from 0.9948 to 0.9998. When a
which the fluorescence intensity of OFX is maximum
concentration of 0.25 mg/ml was determined, in[13] and it does not contain any ion-pair reagents.
spite of the change in the response (above the baseUnder these chromatographic conditions, sufficient level) the integrator did not detect the height at this
resolution was obtained with shorter chromatographic
setting (attenuation 8 and gain 10). Under these
run time (10 min).
operating conditions the detection limit was 0.5 mg/
Fig. 1 shows representative chromatograms of
ml, which in any case was lower than the expecteddrug-free human plasma, and plasma and urine
range for pharmacokinetic studies done up to 8 h.
samples obtained after ingestion of 15 mg/kg of However, the calibration curve was constructed withOFX. The retention time was 7 min. It can be seen the following concentrations, viz. 1.0, 2.5 and 5.0from the chromatograms that both in plasma and
mg/ml for routine assay where therapeutic concen-
urine, OFX is separated as a single peak without its trations can be conveniently interpolated for both
metabolites. OFX is metabolised to three metabolites plasma and urine samples. The reproducibility of the
namely, ofloxacin glucuronide, demethyl ofloxacin
and ofloxacin-N-oxide [11]. In normal individuals
Table 1less than 5% of OFX is excreted in the urine as Calibration curve parameters for OFX in plasma
metabolites [12]. Such low metabolite concentrations
Day Slope Intercept r-valueare of negligible clinical importance and hence no
I 1.22 20.42 0.9949attempt was made to separate them.
II 0.97 20.30 0.9999The calibration curve data and parameters for
III 0.92 20.19 0.9998OFX are given in Table 1. The concentrations of
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Table 2
Linearity and reproducibility of the standards
Standard concentration Mean peak height6SD (RSD, %)
(mg/ml) Plasma (n54) Urine (n54)
1.0 1.3560.11 (8.1) 1.4960.03 (2.0)
2.5 3.4360.18 (5.2) 3.6460.34 (9.1)
5.0 6.8560.48 (7.0) 7.5760.70 (9.4)
three standards used for constructing calibration
graphs for both plasma and urine are given in Table
2. The within-run relative standard deviation (RSD)
ranged from 1.3 to 2.6% and between-run RSD
ranged from 2.4 to 3.4% (Table 3). The recovery
Fig. 2. The mean concentrations of OFX in plasma from healthyranged from 90 to 98% (Table 4).
volunteers.The method described was applied for the de-
termination of OFX concentrations in plasma and
urine from 12 healthy subjects, six of whom were on the natural fluorescence of the quinolone nucleus,
given OFX alone and the rest in combination with which the other anti-tuberculosis drugs namely RMP,
RMP. Fig. 2 presents the mean plasma concentrations INH and PZA do not have.
of OFX at various time intervals. The pharmaco- Fig. 3a compares OFX data obtained by HPLC
kinetic profile is not different for patients who had and MBA assays in plasma. A total of 60 samples
OFX alone or in combination with RMP. The were compared. The mean plasma concentration of
specificity in relation to other anti-tuberculosis drugs OFX was 4.84 mg/ml by HPLC and 4.58 mg/ml by
was not a matter of concern since, the assay is based MBA. This difference was not statistically significant
( p.0.2). However the agreement between the twoTable 3
methods was not very high, as the correlationPrecision of OFX assay in plasma
coefficient was only 0.76.
Concentration RSD Fig. 3b shows the comparison of concentrations inMean6SD (%)
24 urine samples by both the methods. The mean(mg/ml)
concentrations were 236 mg/ml by HPLC and 232Intra-assay precision 1.4060.04 2.6
mg/ml by MBA. The correlation coefficient was3.3460.05 1.3
0.99.5.8260.10 1.7
On the basis of the above values measured by both
Inter-assay precision 1.4060.05 3.4 the methods, the summary measures of OFX namely,
3.2860.08 2.4
area under concentration curve (AUC 0–8 h) and5.8260.19 3.2
proportion (%) of dose excreted over the 0–8 h
period were calculated. The mean values of AUC
were 30.7 and 28.1 mg/ml.h for HPLC and MBA,Table 4
respectively. The proportions (%) of dose excretedRecovery of OFX in plasma
were 39.4 and 37.6% for HPLC and MBA, respec-Added Found Recovery
tively. Neither of the differences was statistically(mg/ml) Mean6SD (%)
(mg/ml) significant ( p.0.2), suggesting either method may
be useful for pharmacokinetics studies.0 1.2660.04
In conclusion, the HPLC method described here1.0 2.2360.19 98
0 3.0460.08 for the determination of OFX in plasma and urine is
2.0 4.8660.28 91 simple, sensitive and precise with an accuracy of
4.0 6.6260.52 90 greater than 90%. The assay is less laborious and
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Fig. 3. (a) Plasma concentrations of OFX (mg/ml) by two methods. (b) Urinary concentrations of OFX (mg/ml) by two methods.
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